Skip to content

A single-center, prospective, randomized controlled clinical trial of iron dextran oral liquid combined with vitamin C in the treatment of iron deficiency anemia during pregnancy

The mechanism and clinical application of iron dextran oral liquid combined with vitamin C in improving iron deficiency during pregnancy through placental trophoblast-immune axis

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600122194
Enrollment
Unknown
Registered
2026-04-10
Start date
2026-04-10
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iron deficiency anemia during pregnancy

Interventions

Iron dextran oral liquid group:Iron dextran oral liquid ( specification according to the clinical commonly used dose setting ), oral, once a day, continuous intervention for 8 weeks.
Iron dextran oral liquid + vitamin C group:On the basis of single drug, combined with oral vitamin C tablets ( specifications according to the clinical routine supplementary dose setting ), once a day

Sponsors

Gansu Provincial Maternity and Child Health Hospital (Gansu Provincial Central Hospital)
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 35 Years

Inclusion criteria

Inclusion criteria: Meet the diagnostic criteria for mild to moderate iron deficiency anemia during pregnancy. Gestational age 16-28 weeks, hemoglobin ( 70-100 g / L ) ; those who had not taken drugs that affected the observation indexes of this study in the past 3 months ; dizziness, fatigue, loss of appetite as the main clinical manifestations.

Exclusion criteria

Exclusion criteria: Those with a history of drug dependence ; patients with severe iron deficiency anemia during pregnancy ; patients with other types of blood diseases ; patients with endocrine diseases ; patients with anemia during pregnancy ; those with a history of pathological blood loss ; patients with infectious diseases ; patients with immune diseases ; those who had a history of blood donation in the past 1 year ; those with a history of drug allergy.

Design outcomes

Primary

MeasureTime frame
Hemoglobin;Serum ferritin;CD4 + / CD8 + T lymphocyte subsets;

Secondary

MeasureTime frame
Soluble transferrin receptor;Serum iron;Transferrin saturation;Treg / Th17 cell ratio;

Countries

China

Contacts

Public ContactChen Mali

Gansu Province Maternity and Child Health Hospital

habe.13_mary@126.com+86 138 9316 1217

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026